Dhaka, Bangladesh (BBN) – The board of directors of Bangladesh’s Ambee Pharmaceuticals has recommended 30 percent cash dividend for the year ended on June 30 in 2017, said an official disclosure on Monday.
The final approval of dividend will come during the annual general meeting (AGM) scheduled to be held on December 21 in Dhaka.
The record date for entitlement of dividend is on November 27 in 2017.
The company has also reported consolidated earnings per share (EPS) of BDT 3.02, consolidated net asset value per share (NAV) per share of BDT 25.24 and consolidated net operating cash flow per share (NOCFPS) of BDT 10.33 for the year ended on June 30 in 2017 which was BDT 3.41, BDT 24.82 and BDT 12.06 respectively for the 18 months period from January 01 in 2015 to June 30 in 2016.
In 2016, the company disbursed 26 percent cash dividend.
There will be no price limit on the trading of the shares of the Company on today following its corporate declaration.
Each share of company, which was listed on the Dhaka bourse in 1986, closed at BDT 409.90 on Sunday last the Dhaka Stock Exchange (DSE).
The company’s paid-up capital is BDT 24 million and authorised capital is BDT 25 million, while the total number of securities is 2.40 million.
Sponsor-directors own 5.26 percent stake in the company while the institutional investors own 2.26 percent and the general public 22.38 percent as on October 31 in 2017, the DSE data shows.
BBN/SS/AD
